Submitter: sold as 5-MeO-DMT expected to be 5-MeO-DMT.
Erowid Expert identified the primary compound as FUB-MDMB (Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3,3- dimethylbutanoate ; a cannabinoid receptor agonist). The secondary compound (8-Hydroxyquinoline) identified is not considered psychoactive.
Lab found two compounds in this white powder and neither were 5-MeO-DMT. Both were initially unidentified but the second compound (2 parts) resembled FUB-PB-22 (a synthetic cannabinoid receptor agonist).
Submitter contacted us to ask about verifying the date and time of delivery and analysis because of dispute with vendor. Sample was dated by submitter on December 15, 2014. It was received by the lab on December 19th, with a post mark from SLO, California. Lab analyzed sample on December 21st and Erowid published results over the next few days as we worked out the unidentifieds in the sample.
The sample was confirmed to contain no 5-MeO-DMT nor any DMT.
Send in a sample for testing
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.
Erowid Expert identified the primary compound as FUB-MDMB (Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3,3- dimethylbutanoate ; a cannabinoid receptor agonist). The secondary compound (8-Hydroxyquinoline) identified is not considered psychoactive.
The sample was confirmed to contain no 5-MeO-DMT nor any DMT.